Aurora Sterilisation has announced the securing of €10.8 million in grants and repayable advances under the IPCEI Tech4Cure programme, operated by Bpifrance. The funding will be used to support medical device manufacturers in transitioning away from conventional sterilisation methods towards a process that is both safer and more environmentally responsible.
The company’s core technology relies on natural plasmas generated from pure air. Unlike widely used sterilisation agents such as ethylene oxide, which carries known toxicity and environmental risks, Aurora’s process uses no hazardous chemicals and operates with low energy consumption. The technology is also designed to be compatible with a wide range of single-use devices, including those made from materials sensitive to heat or moisture, opening the door for manufacturers to bring more complex products to market without being constrained by the limitations of existing sterilisation processes.
“The sterilisation of tomorrow can no longer be separated from the ecological imperative. Our process guarantees maximum patient safety while supporting manufacturers in their transition towards more sustainable solutions and significantly reducing the environmental footprint of sterilisation.”
Jan Laarman, CEO, Aurora Sterilisation
This latest round is the culmination of a consistent funding trajectory since the company’s founding in 2019. Aurora first raised €3 million in equity in December 2021, backed by GO Capital and Normandie Participations. It followed this with a €3 million non-dilutive grant in 2022 under France’s France 2030 plan, then secured a €2.5 million EIC Accelerator grant from the European Innovation Council in 2023, alongside a commitment of up to €10 million in future equity from the EIC fund. A further €3.8 million bond issue was completed in late 2025. The IPCEI round brings Aurora’s total funding raised to over €23 million.
The IPCEI Tech4Cure programme targets cross-border industrial initiatives with the potential to strengthen Europe’s strategic capabilities in healthcare. Aurora’s inclusion signals recognition at the European level that sterilisation infrastructure is part of the continent’s broader health sovereignty agenda. With this funding secured, the company plans to accelerate deployment among European industrial players and scale its operations from its two bases in Rouen and Reims, France, with commercial launch already underway in 2026.